TRANSTHERA-B (02617) announced that, according to the quarterly review results of the Hang Seng Index Series released by Hang Seng Indexes Company Limited on February 13, 2026, the company has been selected and will be included as a constituent in the following, but not limited to, Hang Seng Index Series, effective from March 9, 2026: 1. Hang Seng Composite LargeCap & MidCap Index; 2. Hang Seng LargeCap & MidCap (Investable) Index; 3. Hang Seng Composite MidCap Index; 4. Hang Seng Stock Connect Hong Kong Index; 5. Hang Seng Stock Connect Hong Kong Small & MidCap Index; 6. Hang Seng LargeCap & MidCap Equal Weight QVLM Multi-Factor Index; 7. Hang Seng LargeCap & MidCap Low Volatility All-Share Index; 8. Hang Seng LargeCap & MidCap Momentum All-Share Index; 9. Hang Seng LargeCap & MidCap Quality All-Share Index; 10. Hang Seng LargeCap & MidCap Risk Parity QVLM Multi-Factor Index; 11. Hang Seng LargeCap & MidCap Size All-Share Index; 12. Hang Seng LargeCap & MidCap Value All-Share Index; 13. Hang Seng LargeCap & MidCap Dividend Yield All-Share Index; 14. Hang Seng Stock Connect Hong Kong Mainland Companies Index; and 15. Hang Seng Shanghai-Hong Kong-Shenzhen Connect Biotech 50 Index. Concurrently, the company has been removed from the Hang Seng Composite SmallCap Index, effective from March 9, 2026.
Comments